RO60 and rheumatoid arthritis: Our findings indicate that anti-TROVE2 (anti-Ro60/SSA) antibody could be a useful baseline biomarker for predicting the emergence of ADAb and secondary therapeutic failure in adalimumab-treated RA patients.